Program
IDP-126
A development code. Also written as “IDP-126 Gel”, “CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.” and “IDP-126 Component A”.
Its studies are mostly in Acne Vulgaris, led by Bausch Health Companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bausch Health Companies | 61 open or running | phase 4since Feb 5, 2026 | May 26, 2017 | Dec 2027phase 4 · NCT07524946 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 26, 2017First study: phase 2 study in Acne VulgarisFirst studyNCT03170388 · 741 enrolled · United States, Canada
- Aug 20, 2018Phase 1 study in Acne VulgarisNCT03653403 · 61 enrolled · United States
- Dec 30, 20192 phase 3 studies in Acne VulgarisNCT04214652, NCT04214639
- May 14, 2021Phase 2 study in Acne VulgarisNCT04892706 · 686 enrolled · United States, Belgium, Canada
- Feb 5, 2026Phase 4 study in Acne VulgarisNCT07524946 · 100 planned · United States
Ahead
- Dec 2027Primary completion: phase 4 study in Acne VulgarisNCT07524946
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07524946Acne Vulgaris · United States | 4 | Recruiting | Dec 2027 | 100 |
| NCT04892706Acne Vulgaris · United States, Belgium, Canada | 2 | Completed | Sep 28, 2022 | 686 |
| NCT04214652Acne Vulgaris · United States, Canada | 3 | Completed | Mar 18, 2021 | 180 |
| NCT04214639Acne Vulgaris · United States, Canada | 3 | Completed | Jan 18, 2021 | 183 |
| NCT03653403Acne Vulgaris · United States | 1 | Completed | Jun 19, 2019 | 61 |
| NCT03170388Acne Vulgaris · United States, Canada | 2 | Completed | Apr 23, 2019 | 741 |
How it is read
Names in the registry
- “IDP-126 Gel”, 5 entries
- “CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.”, 1 entry
- “IDP-126 Component A”, 1 entry
- “IDP-126 Component B”, 1 entry
- “IDP-126 Component C”, 1 entry
Codes read as this program: IDP126.
Conditions, from the studies’ own filings
- Acne Vulgaris, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.